This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Celik, I. Articles by Kisker, O. Search for Related Content PubMed PubMed Citation Articles by Celik, I. Articles by Kisker, O.

Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve

¹ Institute of Theoretical Surgery and ² Department of General Surgery, University Hospital Marburg, Philipps University, Baldingerstrasse, Marburg; ³ Charité, Department of Obstetrics and Gynecology, Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany; ⁴ Vascular Biology Program and Department of Surgery, Children's Hospital Boston, Harvard Medical School; ⁵ Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School; and ⁶ Dana-Farber Cancer Institute, Boston, Massachusetts

Requests for reprints: Ilhan Celik, Institute of Theoretical Surgery, Philipps-University Marburg, Baldingerstrasse, D-35043 Marburg, Germany. Phone: 49-6421-286-2229; Fax: 49-6421-286-8926; E-mail: Celik{at}mailer.uni-marburg.de.

We show here that recombinant endostatin protein has a biphasic effect on the inhibition of endothelial cell migration in vitro. In tumor-bearing animals, there is a similar biphasic effect on the inhibition of tumor growth and on circulating endothelial cells after once-daily s.c. injections. This biphasic effect is revealed as a U-shaped curve in which efficacy is optimal between very low and very high doses depending on the tumor type. This result may be applicable to other inhibitors of endothelial growth and to angiogenesis. Furthermore, these results have important implications for clinicians who administer angiogenesis inhibitors for cancer or other angiogenesis-dependent diseases. When these results are taken together with two previous reports of angiogenesis inhibitors with a U-shaped dose-response, they suggest that other regulators of endothelial growth may display a similar pattern.

This article has been cited by other articles:

				O.-N. Bae, K.-M. Lim, J.-Y. Han, B.-I. Jung, J.-Y. Lee, J.-Y. Noh, S.-M. Chung, M.-Y. Lee, J.-Y. Lee, and J.-H. Chung U-shaped Dose Response in Vasomotor Tone: A Mixed Result of Heterogenic Response of Multiple Cells to Xenobiotics Toxicol. Sci., May 1, 2008; 103(1): 181 - 190. [Abstract] [Full Text] [PDF]

				F. Donate, G. C. Parry, Y. Shaked, H. Hensley, X. Guan, I. Beck, Z. Tel-Tsur, M. L. Plunkett, M. Manuia, D. E. Shaw, et al. Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth Clin. Cancer Res., April 1, 2008; 14(7): 2137 - 2144. [Abstract] [Full Text] [PDF]

				T.-Y. Lee, R. M. Tjin Tham Sjin, S. Movahedi, B. Ahmed, E. A. Pravda, K.-M. Lo, S. D. Gillies, J. Folkman, and K. Javaherian Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy Clin. Cancer Res., March 1, 2008; 14(5): 1487 - 1493. [Abstract] [Full Text] [PDF]

				J. Folkman Endostatin finds a new partner: nucleolin Blood, October 15, 2007; 110(8): 2786 - 2787. [Full Text] [PDF]

				C.R. Dass, T.M.N. Tran, and P.F.M. Choong Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics Journal of Dental Research, October 1, 2007; 86(10): 927 - 936. [Abstract] [Full Text] [PDF]

				J. V. Heymach, B. E. Johnson, D. Prager, E. Csada, J. Roubec, M. Pesek, I. Spasova, C. P. Belani, I. Bodrogi, S. Gadgeel, et al. Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2007; 25(27): 4270 - 4277. [Abstract] [Full Text] [PDF]

				M. H. Kulke, E. K. Bergsland, D. P. Ryan, P. C. Enzinger, T. J. Lynch, A. X. Zhu, J. A. Meyerhardt, J. V. Heymach, W. E. Fogler, C. Sidor, et al. Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., August 1, 2006; 24(22): 3555 - 3561. [Abstract] [Full Text] [PDF]

				W. J. van Heeckeren, S. Bhakta, J. Ortiz, J. Duerk, M. M. Cooney, A. Dowlati, K. McCrae, and S. C. Remick Promise of New Vascular-Disrupting Agents Balanced With Cardiac Toxicity: Is It Time for Oncologists to Get to Know Their Cardiologists? J. Clin. Oncol., April 1, 2006; 24(10): 1485 - 1488. [Full Text] [PDF]